Integrated Oncology Learning - Activity Details

1. Read the Activity Overview
2. Take the Pretest
3. Take the Activity
4. Take the Posttest/Evaluation
5. View/Print CME Certificate

To begin this acvivity, please choose a participation option at the bottom of this page.

Defining New Therapeutic Options for Chronic Lymphocytic Leukemia
Online Only Cancer Summaries & Commentaries Vol. 2, No. 2

This activity is not sanctioned by, nor a part of, the 50th Annual Meeting of the American Society of Hematology.

Release Date: March 10, 2009
Expiration Date: March 10, 2010

Table of Contents

Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia
Reviewed by: Stephan Stilgenbauer, MD
Medical writer: Sabeeha Muneer, PhD

Fludarabine/Cyclophosphamide Compared to Fludarabine/Cyclophosphamide/Rituximab in Chronic Lymphocytic Leukemia: Results From 2 Phase III Trials
Medical writer: Bing-e Xu, PhD
Reviewed by: Stephan Stilgenbauer, MD

Efficacy and Safety of Ofatumumab in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Medical writer: Aarati Ranganathan, PhD
Reviewed by: Stephan Stilgenbauer, MD

Phase II Trial of Subcutaneous Alemtuzumab in Patients With Fludarabine-Refractory Chronic Lymphocytic Leukemia
Medical writer: Marissa Shrader, PhD
Reviewed by: Stephan Stilgenbauer, MD

Trials of Monoclonal Antibodies in Relapsed/Refractory Chronic Lymphocytic Leukemia
Medical writer: Sabeeha Muneer, PhD
Reviewed by: Stephan Stilgenbauer, MD

Instructions for Participation

1. Read the following information before entering the educational activity.
2. Complete the Pretest.
3. Study the educational activity.
4. Complete the Posttest.
5. Answer the evaluation questions.
6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

You will be asked to login
or create an account.